Trial Profile
A Clinical Trial of Pembrolizumab in Patients With Hepatitis B Virus-related Hepatocellular Carcinoma, With Parallel Study on Baseline and Serial Change in the Immune Environment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 Nov 2023 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
- 21 Nov 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
- 21 Nov 2023 Status changed from recruiting to active, no longer recruiting.